This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2001 Nov 13;165(10):1293, 1295.

Postmarketing drug surveillance: what it would take to make it work

No authors listed

PMID: 11760966
PMCID: PMC81607

Editorial

Postmarketing drug surveillance: what it would take to make it work

No authors listed. CMAJ. 2001.

. 2001 Nov 13;165(10):1293, 1295.

PMID: 11760966
PMCID: PMC81607

No abstract available

PubMed Disclaimer

Similar articles

Postmarketing surveillance study of a non-chlorofluorocarbon inhaler Postmarketing surveillance studies remain unethical.
Patterson C. Patterson C. BMJ. 1999 Mar 20;318(7186):810-11. BMJ. 1999. PMID: 10215393 No abstract available.
Postmarketing surveillance for drug safety: surely we can do better.
Griffin MR, Stein CM, Ray WA. Griffin MR, et al. Clin Pharmacol Ther. 2004 Jun;75(6):491-4. doi: 10.1016/j.clpt.2004.01.017. Clin Pharmacol Ther. 2004. PMID: 15179403 Review. No abstract available.
["There are clear criteria for product surveillance studies"].
Throm S. Throm S. MMW Fortschr Med. 2009 Aug 20;151(34-35):7. MMW Fortschr Med. 2009. PMID: 19771777 German. No abstract available.
The ethical issues of the postmarketing surveillance of drug teratogenicity in Hungary.
Czeizel AE. Czeizel AE. Pharmacoepidemiol Drug Saf. 2001 Dec;10(7):635-9. doi: 10.1002/pds.635. Pharmacoepidemiol Drug Saf. 2001. PMID: 11980253
Data quality in post-marketing surveillance.
Girard M. Girard M. Adverse Drug React Acute Poisoning Rev. 1986 Summer;5(2):87-95. Adverse Drug React Acute Poisoning Rev. 1986. PMID: 3529880 Review. No abstract available.

See all similar articles

Cited by

Drug safety without borders: concerns about bupropion.
Mintzes B, Bassett K, Wright JM. Mintzes B, et al. CMAJ. 2002 Sep 3;167(5):447. CMAJ. 2002. PMID: 12240797 Free PMC article. No abstract available.
Adverse drug reaction reporting controversy.
Appel WC. Appel WC. CMAJ. 2002 Apr 2;166(7):884-5. CMAJ. 2002. PMID: 11949980 Free PMC article. No abstract available.
We need Romanow's National Drug Agency.
[No authors listed] [No authors listed] CMAJ. 2003 Feb 4;168(3):249, 251. CMAJ. 2003. PMID: 12566321 Free PMC article. No abstract available.

References

1. Kohn LT, Corrigan JM, Donaldson MS, editors. To err is human: building a safer health system. Committee on Quality of Health Care in America, US Institute of Medicine. Washington: National Academy Press; 2000. - PubMed
1. Hunter D, Bains N. Rates of adverse events among hospital admissions and day surgeries in Ontario from 1992 to 1997. CMAJ 1999;160 (11): 1585-6. Available: www.cma.ca/cmaj/vol-160/issue-11/1585.htm - PMC - PubMed
1. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000; 284 (23):3036-9. - PubMed
1. Sibbald B. Cisapride, before and after: still waiting for ADR reform. CMAJ 2001;165(10):1370-1.
1. Buffie E, Swerhone E, directors. Drug deals: the brave new world of prescription drugs [film]. Toronto: National Film Board of Canada; 2001.

Publication types

Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources